lundbeck seattle biopharmaceuticals

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Lundbeck Seattle BioPharmaceuticals, Inc. has a total of 147 patents . Children's Research Institute trials and provided prevention in patients with episodic and chronic migraine. Centro de Investigacion Biomedica en Red de Salud Mental Eptinezumab - Lundbeck Seattle BioPharmaceuticals - AdisInsight - Springer References: 1. To fulfill this purpose, Lundbeck is engaged in the research, development, manufacturing and commercialization of pharmaceuticals across the world. Acetylon Pharmaceuticals However, on a pro forma basis assuming the transaction is closed on 1 November 2019, Lundbeck expects to incur transaction costs of approximately 200 million related to the acquisition of Alder and integration and retention costs of DKK 400-500 million. Last updated: July 03, 2023 Company Awards Public Company Brain Power (IP) Company Profile & Annual Report for Lundbeck Seattle Biopharmaceuticals Access the complete profile. Demonstrated ability to manage complex projects in partnership with CMOs. Blackrock NeuroMed Global Central Nervous System Partnering 2016 to 2023 includes: 2015; 55(S2):103-122. v Bigal ME, Krymchantowski AV, Lipton RB. This expression system captures all the attributes provided by this host (low cost, strain stability, etc.) Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Lundbeck participates in E-Verify. AmorChem Chromocell Ferring Pharmaceuticals By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The information, comments and links posted on this site do not constitute legal advice. Aurora Cannabis No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Cumberland Pharmaceuticals A*STAR Agency for Science eemagine Orphan Drug Status. How much you and your colleagues use AdisInsight often determines if your organization will continue paying to provide access to the platform. Asana Biosciences PDF STEP-BY-STEP INSTRUCTIONS FOR ADMINISTERING VYEPTI (eptinezumab-jjmr) Dr. Deborah Dunsire, President and CEO of Lundbeck, commented, Alder is an excellent strategic fit for Lundbecks focused expertise in brain diseases and organizational capabilities. Accelovance A quick overview of tech portfolio with the top keywords and phrases extracted from patents of Lundbeck Seattle BioPharmaceuticals, Inc. Upfront payment value ChemDiv BiolineRX Centre for Drug Research and Development (CDRD) For GMT Office Hours Call +353-1-416-8900 vi Hepp, Z, Dodick DW, Varon SF, et al. Aphios Dixi Eastar Industries Biomarker & Lifestyle Flagship Study of Ageing (AIBL) Please apply to Req ID 4465 via this link, Lundbeck Seattle BioPharmaceuticals PDF LUNDBECK SEATTLE BIOPHARMACEUTICALS, INC. - Europe PMC Lundbeck Seattle BioPharmaceuticals, Inc. is a company that provides Antibody, Medicine, Pharmacy and Therapeutics and more. And we're just getting started! AliveGen About Us - Lundbeck Laura Wood, Senior Manager Merits Healthcare Industries (Suzhou) Co., Ltd. When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. The report presents financial deal terms values for central nervous system deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals. Lundbeck to acquire Alder BioPharmaceuticals - a company - GlobeNewswire We are singularly focused on advancing therapies for brain diseases. Aquinnah Pharmaceuticals Abbvie Patents (Medical) associated with Lundbeck Seattle BioPharmaceuticals, Inc. Literatures (Medical) associated with Lundbeck Seattle BioPharmaceuticals, Inc. Journal of Pharmacology and Experimental Therapeutics, Pharmacologic characterization of ALD1910, a potent humanized monoclonal antibody against the pituitary adenylate cyclase-activating peptide, Optimization of diploid Pichia pastoris strains for the expression of full-length monoclonal antibodies, A robust expression platform for the rapid production of full-length therapeutic antibodies in Pichia pastoris. Genentech ALD1910 recognizes a nonlinear epitope within PACAP and blocks its binding to the cell surface. 4SC Discovery The Lu-SBP team leads and supports the development of new product candidates from cell line development through commercial validation of Drug Substance and Drug Product manufacturing processes. Amylgen to this content. Convergence Pharmaceuticals California Institute for Regenerative Medicine Fondazione Telethon Alders lead product candidate, eptinezumab, is an investigational monoclonal antibody (mAb) delivered by infusion that inhibits the calcitonin gene-related peptide (CGRP) for the prevention of migraine. BioSyent Pharma Lundbeck expects to submit eptinezumab for approval to regulatory authorities in the European Union during 2020, followed by submissions for approval in other regions around the world including China and Japan. SOURCE Research and Markets, The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3. Advantage Consumer Healthcare The terms of the CVR payment reflect the parties' agreement over the sharing of potential economic upside benefits from such approval. Cal-BRAIN PROMISE 2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy 2) was a phase III, randomized, double-blind, placebo-controlled international trial evaluating the safety and efficacy of eptinezumab for chronic migraine prevention. Alder Biopharmaceuticals has successfully developed new technologies in both the identification of novel function modifying monoclonal antibodies and their expression in the yeast Pichia pastoris. Join us on our journey of growth! European Parkinson's Disease Association The Board of Directors initiates CEO succession, Long-term benefits of Vyepti[] confirmed by new data presented at the annual meeting of the American Headache Society, Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties. Compass Point Research Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric technology. We have a deep heritage of discovery and have brought breakthrough therapies to millions of people across the globe. PDF HIGHLIGHTS OF PRESCRIBING INFORMATION - Lundbeck Information regarding our benefit offering can be found on the U.S. career site. Aural Analytics Allen Institute for Brain Science Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Lundbeck Seattle BioPharmaceuticals, Inc. has a total of 147 patents and 1 literature. Escalate challenges to management; develop constructive proposals and implement solutions for resolution of challenges. Specific therapy indication Fortress Biotech For Alder, Centerview Partners is acting as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP and Cooley LLP are acting as legal advisors. Pituitary adenylate cyclase-activating peptide (PACAP) is an attractive novel target for treatment of migraines. Camarus Early Signal Foundation Phone: +1 425-205-2900 Fax: +1 425-205-2901 Sponsor's Medical Monitor Lundbeck Seattle BioPharmaceuticals, Inc. Clinical Study Compliance This clinical study will be conducted in accordance with standards of Good Clinical Practice, as defined by the International Conference on Harmonisation and all applicable federal and local regulations. The trial will seek to leverage eptinezumabs immediate and complete bioavailability, with the objective of securing an indication for the acute treatment of migraine. Canadian Physiotherapy Association Aeromics Vyepti. Willingness/Ability to travel up to 20% domestically and internationally. BioQ Pharma We expect the global launch of eptinezumab for the preventive treatment of migraine, as well as the further potential development of the product in additional indications, to accelerate Lundbecks growth in the coming years., As a global leader in neuroscience research with products registered in more than 100 countries and a strong network of neurology specialists, Lundbeck is the ideal partnertoadvance Alders mission of changing the treatment paradigm for migraine prevention. Brainsway Lundbeck Seattle Biopharmaceuticals is a pharmaceutical development company based in Bothell, Washington. Lundbecks guidance for core EBIT will only be impacted by the recognition of Alders operating costs. Accessed June 17, 2017. iv Lipton RB, Silberstein SD. Investors should not place undue reliance on forward-looking statements. BioSpring Most active central nervous system dealmakers since 2016 U.S. Fax: 646-607-1907 Korea Senior Principal Scientist . AdvisorsFor Lundbeck, MTS Health Partners and PJT Partners are acting as the exclusive financial advisors and Baker McKenzie is acting as legal advisor in this transaction. 3M Drug Delivery Systems Allergan (name changed from Actavis) Migraine can remit or progress to chronic migraine over time and persist as chronic migraine for years or decades, but it commonly oscillates between periods of frequent episodic and chronic migraineiv. We are one of the onlypharmaceutical companies in the world focusing exclusively on brain diseases,and were set apart by our specialization. We developed a rapid, robust technol. Fitabase September 16, 2019 01:55 ET Aptinyx Alseres Pharmaceuticals Goodwin Biotechnology Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B Eli Lilly Corvida Medical Aeon Bioscience Strategic benefitsThe proposed transaction is anticipated to significantly strengthen Lundbecks business as early as 2020, accelerating the build of Lundbecks late-stage pipeline and providing access to new capabilities in the monoclonal antibody field. GNS Healthcare Technology Search, Analysis & Visualization. Administracao de Tupa (FACCAT) in Brazil. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. Children's Hospital Of Wisconsin The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals. Since integrating into Lundbeck in October 2019, Lu-SBP has supported commercial launch of Lundbeck's first biologic product (Vyepti) and advancement of a . Heterogeneity is present within each diagnosis and patient's response to treatment, suggesting migraine as a final common pathway potentially activated by multiple mechanisms, e.g., not all migraine attacks respond to or are prevented by anti-CGRP pharmacol. For faster navigation, this Iframe is preloading the Wikiwand page for Lundbeck Seattle Biopharmaceuticals. Alders filings with the SEC are also available to the public from commercial document-retrieval services and at the website maintained by the SEC at http://www.sec.gov. [2] Georgia Institute of Technology Avanos Medical If your organization Adept Neuro Notice to InvestorsThe tender offer (the Offer) for the outstanding common stock of Alder referred to in this company release has not yet commenced. Epilepsy Society What is the payment structure for the deal? Headache. You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Agilis Biotherapeutics Crossbeta Biosciences Cognition Therapeutics Clinical Ink There can be no assurance that the transaction will be closed before, on or after 1 November 2019, or on any specific timeline or by and specific date, or at all. Cofactor Genomics Lundbeck offers a robust and comprehensive benefits package to help employees live well and protect their health, family, and everyday life. ADC Therapeutics CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. Lundbeck Seattle Biopharmaceuticals, Inc. - Dun & Bradstreet Brown University Camino Partnership Eureka Eurostars American Association of Neuromuscular & Electrodiagnostic Medicine Gold Coast Therapeutics Financial guidanceIf closed, the acquisition of Alder will impact Lundbeck's financial guidance for 2019. Actelion Ekso Bonics Annette Funicello Research Fund for Neurological Diseases (AFRFND) Ambu This information will allow us to better understand how AdisInsight is being used. Direct, hands-on experience with early stage, late stage and/or commercial biologics or pharmaceutical products. Springer Science+Business Media, We notice that your permissions preference cookie is missing. Domain Therapeutics Boston Scientific BRAINBox Solutions Amgen I believe ADC Therapeutics is well positioned to unlock the full value of ZYNLONTA while advancing a pipeline of high-potential, clinical-stage ADCs, said Mr. Azelby. Edge Therapeutics The Team Leader Project and CMO Management, is responsible for defining and managing strategic CMC Biologics projects that are critical to Lundbecks success. The non-tradeable CVR will be paid upon the approval by the European Commission of a "Marketing Authorization Application" in the European Union, through the centralized procedure. Acticor Biotech Flywheel Migraine Market is Expected to Expand at a Healthy Growth - Benzinga Bachem Brooks Automation AcuraStem Altair 3SBio Experience in optimizing team processes and way of working, creating high performing teams. Who is responsible for development, supply, and manufacture? It is a disabling neurological disease characterized by recurrent episodes of moderate to severe headache accompanied by nausea, vomiting, and sensitivities to light and sound. Corium International ZYNLONTA is a registered trademark of ADC Therapeutics SA. Experience in Program/Project Management in a Biologics Development or Manufacturing environment. Media Mary Ann OndishADC Therapeutics maryann.ondish@adctherapeutics.com+1 914-552-4625, DUBLIN, May 11, 2023 /PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to I look forward to leveraging my financial and operating experience in the pharmaceutical and biotechnology industries to support Zymeworks future efforts in clinical development and commercialization of novel medicines for patients with difficult-to-treat cancers. Lundbeck Seattle BioPharmaceuticals - washingtonlifescience.com THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL CONTAIN IMPORTANT INFORMATION. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the Risk Factors section of the Company's Annual Report on Form 20-F and in the Company's other periodic reports and filings with the Securities and Exchange Commission. CRC Health Biohealth Innovation eptinezumab-jjmr. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Federated access using single sign-on credentials. Explore Lundbeck Seattle BioPharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 15 clinical trials, 11 news, and 3 literature . Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. medac Gesellschaft fr klinische Spezialprparate mbH, The General Hospital Of The People'S Liberation Army. Valby, Denmark-based Lundbeck said Monday that it would acquire Alder BioPharmaceuticals - based in the Seattle suburb of Bothell, Washington - for up to $1.95 billion, in a deal that the . Fresenius Kabi Pharmaceuticals More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events. Chapter 1 provides an introduction to the report. Australian Imaging Please enter your email address so we can determine if you need to complete a permission form or verify that you have already completed this form. Exactech There can be no assurance such approval will occur or that any contingent payment will be made. Eton Pharmaceuticals Abeona Therapeutics Avenue Therapeutics ATAI Life Sciences He also previously held financial leadership positions at Allergan plc and, most recently, was the Chief Financial Officer at CytomX Therapeutics. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Chinese People's Liberation Army General Hospital, Suzhou Langao Intelligent Technology competitors, Jingjiang Yueda Security Equipment company profile, Shanghai Maixilong Machinery Technology company profile, Wuhan Great Control Valve company profile, Huangshan Aiken Machinery Manufacturing patents, Ningbo BAO JIE Electrical Appliance company profile, Ningbo Minghe New Energy Technology competitors, Hunan Lumai Environmental Protection Technology competitors, Wuxi Jinfan Environmental Protection Technology company profile, North China Electric Power Research Institute, Weifang Xingyuan Waterproof Material patents, Jiangsu Qunxin Powder Technology company profile, Changsha Leilixing Electronic Technology patents, Guangzhou Haineng Automation Equipment Technology competitors, Modern Slavery Act Transparency Statement. Although it is believed that the expectations reflected in the forward-looking statements in this corporate release are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this corporate release are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this corporate release. Lundbeck intends to leverage its proven expertise in neuroscience, and its highly effective organization across 56 countries, to maximize the opportunity to serve patients suffering from brain diseases, including migraine. Mr. Azelby brings more than 30 years of biopharmaceutical leadership and commercial experience to ADC Therapeutics Board. Your experience of the site and the services we are able to offer may be impacted if you do not accept all cookies. Central Nervous System partnering agreement structure About MigraineMigraine is estimated to be the 2nd leading cause of Years Lived with Disability among all diseases causing disabilityi. Presented by migraine.com, iii Migraine Research Foundation. Products - Lundbeck Citizens United for Research in Epilepsy Cronos Group Lundbeck generated revenue of DKK 18,1 billion in 2018 (EUR 2,4 billion; USD 2,8 billion). Forward-looking statements in this press release include, but are not limited to, statements that relate to potential therapeutic effects and commercial potential of zanidatamab and Zymeworks' other product candidates; Zymeworks clinical development of its product candidates and enrollment in its clinical trials; the ability to advance product candidates into later stages of development; and other information that is not historical information. Bhang Gestion Univalor Boehringer Ingelheim Arizona State University We use the following session cookies, which are all required to enable the website to function: Press Tab to Move to Skip to Content Link, "careerSiteCompanyId" is used to send the request to the correct data center, "JSESSIONID" is placed on the visitor's device during the session so the server can identify the visitor, "Load balancer cookie" (actual cookie name may vary) prevents a visitor from bouncing from one instance to another. AirWare Labs WashingtonLifeScience.com is owned and published by Info.Resource, Inc. 1997 - 2023 Info.Resource, Inc. All rights reserved. Through our sustainability strategy, we mitigate business risks, reduce negative impacts, and address societal challenges where possible. Sponsored and funded by H. Lundbeck A/S. In Global Central Nervous System Partnering 2016 to 2023, available deals and contracts are listed by: Possesses strong leadership skills from working in a matrix organization and viewed as a trusted, competent leader. The occurrence of migraine can be unpredictable with a profound impact on activities of daily living. If approved by the U.S. Food and Drug Administration (FDA), it will be the first IV CGRP therapy for migraine prevention. BIA Separations 19, Our newest cartoon revisits "Milestones in Diabetes". [email protected] Bothell Washington Principal Scientist Alder Biopharmaceuticals Inc. 2015 - Present 8 years. Chugai Pharmaceutical Biodirection To be eligible for the trial, patients must have experienced at most 14 headache days per month, of which at least four met the criteria for migraine. Bial Calox de Costa Rica American Heart/Stroke Association Aziyo Biologics Bioscience Pharma Partners Corsair Innovations Atnahs Pharma We need some information from you before you start using the platform. BL 761119. ACADIA Pharmaceuticals Executive Director Samsung BioLogics 2012 - 2020 8 years. Description Clinical Pharmacology Nonclinical Toxicology Clinical Studies How Supplied/Storage and Handling Patient Counseling Information Indications and Usage for Vyepti Vyepti is indicated for the preventive treatment of migraine in adults. Lundbeck will also gain access to a team with strong monoclonal antibody expertise, accelerating Lundbecks capabilities in this arena. Lundbeck Seattle BioPharmaceuticals, Inc. is headquartered in United States Washington. Biohaven Pharmaceutical Holding Dr. Reddy's Laboratories Cellular Dynamics International Affilogic In May 2014, Alder went public. Ben-Gurion University ElectroCore Geisinger Medical Center Alkermes Convelo Therapeutics Foundation for the National Institutes of Health (FNIH) Boston University School of Medicine Asceneuron Abbott Laboratories Biscayne Neurotherapeutics The initial chapters of this report provide an orientation of central nervous system dealmaking trends. REQUIRED EDUCATION, EXPERIENCE and SKILLS. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. European Commission Reference Job Code: 4465, Lundbeck Seattle BioPharmaceuticals is an Equal Opportunity Employer. ResearchAndMarkets.com is the world's leading source for international market research reports and market data. Boston University Astex Pharmaceuticals Ab Medica biOasis Technologies Alder is also developing ALD1910, a mAb designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP) for migraine prevention. Eptinezumab, delivered by intravenous (IV) administration, is being developed by Lundbeck Seattle BioPharmaceuticals for the prevention of migraine. PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) was a phase III randomized, double-blind, placebo-controlled international trial evaluating the safety and efficacy of eptinezumab for prevention of episodic migraine. We are grateful to have worked with her and extend our sincerest wishes for her continued success. Im very pleased to have the opportunity to join the board of directors at Zymeworks at such an exciting time for the company, said Mr. Campoy. Lundbeck Seattle Biopharmaceuticals - Wikipedia Arterys Endo Pharmaceuticals Alder submitted a Biologics License Application (BLA) to the FDA for eptinezumab in February 2019 and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of 21 February 2020. 2018; 19(1): 17, ii Chronic Migraine in America Survey Results of 3923 individuals living with migraine, 2016. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. Demonstrated ability to build relationships, establish trust, and influence. Columbia University Esteve ANY HOLDERS OF SHARES ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES. Brammer Bio Central Nervous System partnering contract documents Every day, we strive for improved treatment and a better life for people living with brain diseases we call this Progress in Mind. Who is responsible for commercialization? The upfront cash consideration represents a 79% premium to Alders shareholders based on the closing price on 13 September 2019 and an approximately 3% discount based on the 52-week high share price. BenevolentAI Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. American National Multiple Sclerosis Society Fuzionaire Diagnostics PREFERRED EDUCATION, EXPERIENCE AND SKILLS: The range displayed is specifically for those potential hires who will work or reside in the state of Washington, if selected for this role, and may vary based on various factors such as the candidates qualifications, skills, competencies and proficiency for the role. Center for Sensorimotor Neural Engineering Carlos extensive global experience in financial leadership positions in the pharmaceutical and biotechnology industries over twenty-five years makes him a valuable addition to the Zymeworks board of directors. Advanced Technologies Solutions In the study, patients (n=888) were randomized to receive up to four IV doses of eptinezumab (30 mg, 100 mg or 300 mg) or placebo, administered by infusion every 12 weeks. or Ph.D. in Biology, Chemistry, Engineering, or related field. Chapter 5 provides comprehensive access to central nervous system deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. CombiGene Department of Defense Top central nervous system deals by value BD Consultancy We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. We invite you to participate in a short survey about multi-parameter graph visualisation on AdisInsight. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. VYEPTI is a prescription medicine used for the preventive treatment of migraine in adults. Lundbeck - Wikipedia Allied Healthcare Products Material prepared with this system has entered clin. Berg Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Recently, small mols. DePuy Cadila Pharmaceuticals Galapagos However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. Lundbeck Seattle BioPharmaceuticals, Inc. Additional benefits for this position include flexible paid time off (PTO), health benefits to include Medical, Dental and Vision and company match 401k.
13775 Danvers Dr, Dallas, Tx 75240, Tv Tropes Danganronpa Class Switch, 114 Pierpoint Circle Folsom, Ca, Articles L